Haloperidol Injection

  • Psychosis

Haloperidol Injection Generic Name & Formulations

General Description

Haloperidol (as lactate) 5mg/mL; for IM inj.

Pharmacological Class


How Supplied

Inj—contact supplier; Decanoate 50 (1mL amps)—3; Decanoate 100 (1mL amps)—5

Haloperidol Injection Indications



Haloperidol Injection Dosage and Administration


Individualize. 2–5mg IM every 4–8hrs or up to hourly if needed; max: 20mg/day. Switch to oral form 12–24hrs after last injection.


Not established.

Haloperidol Injection Contraindications


Severe toxic CNS depression. Coma. Parkinson's disease. Dementia with Lewy bodies.

Haloperidol Injection Boxed Warnings

Boxed Warning

Increased mortality in elderly patients with dementia-related psychosis.

Haloperidol Injection Warnings/Precautions


Elderly with dementia-related psychosis (not approved use): increased risk of death or cerebrovascular reactions (eg, stroke, TIA). Risk of QT prolongation: electrolyte disturbances (eg, hypokalemia, hypomagnesemia), underlying cardiac abnormalities, hypothyroidism, familial long QT-syndrome. Increased risk of Torsades de Pointes if QT interval >500msec. Seizures. Thyrotoxicosis. Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline or ANC <1000/mm3. Severe cardiovascular disorders. Mania. Perform fall risk assessments when initiating and recurrently on long-term therapy. Hepatic impairment. Debilitated. Avoid abrupt cessation. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy. Nursing mothers: not recommended.

Haloperidol Injection Pharmacokinetics

See Literature

Haloperidol Injection Interactions


CNS depression potentiated with alcohol (avoid), anesthetics, opioids, other CNS depressants. Possible neurotoxicity with lithium: monitor, discontinue if occurs. Caution with drugs that prolong the QT interval (eg, Class 1A [eg, procainamide, quinidine, disopyramide] or Class 3 antiarrhythmics [eg, amiodarone, sotalol], citalopram, erythromycin, levofloxacin, methadone, ziprasidone, ketoconazole, paroxetine). Caution with drugs known to cause electrolyte imbalance (eg, diuretics, corticosteroids). May be potentiated by CYP3A4 or CYP2D6 inhibitors/substrates (eg, itraconazole, ketoconazole, nefazodone, alprazolam, chlorpromazine, promethazine, quinidine, paroxetine, sertraline, venlafaxine, fluoxetine, fluvoxamine, ritonavir, buspirone); monitor. May be antagonized by CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John’s wort); monitor and adjust doses. May potentiate CYP2D6 substrates (eg, desipramine, imipramine). May impair effects of levodopa, other dopamine agonists. May increase intraocular pressure with anticholinergics, antiparkinson agents. Monitor anticoagulants.

Haloperidol Injection Adverse Reactions

Adverse Reactions

Tardive dyskinesia, neuroleptic malignant syndrome, extrapyramidal symptoms, hyperpyrexia, heat stroke, bronchopneumonia, cardiovascular effects, hematological effects, GI upset, anticholinergic effects; QT prolongation, Torsades de Pointes, dystonia, hypersensitivity reactions, cerebrovascular reactions.

Haloperidol Injection Clinical Trials

See Literature

Haloperidol Injection Note


Formerly known under the brand name Haldol.

Haloperidol Injection Patient Counseling

See Literature